Fig. 6

A trial sequential analysis (TSA) for 16 studies assessing the incidence of MACE of which the cumulative Z-line on the curve did not cross either the conventional boundaries of benefit nor the trial sequential monitoring boundaries for any interventions, suggesting that DCB is not-inferior to DES, and further large volume RCTs should be carried out to validate our results. A diversity-adjusted required information size of 5,478 patients was calculated using an alpha error of 0.05, a beta error of 0.20 (power 80%), and a control event proportion of 9.9%, as calculated from the control group in this meta-analysis